Background: The aim of this study was to investigate the association between branched-chain amino acid (BCAA) intake and markers of insulin metabolism in adults. Methods: This cohort study was conducted within the framework of the Tehran Lipid and Glucose Study on 1205 subjects, aged ≥20 years, who were followed-up for a mean of 2.3 years. Dietary intake of BCAAs, including valine, leucine, and isoleucine, was determined using a valid and reliable food frequency questionnaire. Hyperinsulinemia, β-cell dysfunction, insulin resistance (IR), and insulin insensitivity were determined according to optimal cut-off values. Logistic regression was to estimate the occurrence of IR across tertiles of BCAA intake. Results: The mean (AE SD) age and BCAA intake of participants (43% male) at baseline were 42.7 AE 13.1 years and 13.8 AE 5.1 g/day, respectively. The incidence of hyperinsulinemia, β-cell dysfunction, insulin insensitivity, and IR was 19.5%, 24.0%, 28.0%, and 12.5%, respectively. After adjustment for confounding variables, subjects in the highest tertile for total BCAAs (odds ratio [OR] 1.67; 95% confidence interval [CI] 1.03-2.71), leucine (OR 1.75; 95% CI 1.09-2.82), and valine (OR 1.61; 95% CI 1.01-2.60) intake had a greater risk of incident IR than subjects in the lowest tertile. A higher intake of isoleucine was not associated with risk of incident IR. There was no association of total BCAAs, leucine, isoleucine, and valine intake with the risk of hyperinsulinemia, insulin insensitivity, or β-cell dysfunction. Conclusion: The findings of this study support the hypothesis that higher intakes of BCAAs may have adverse effects on the development of IR.
Introduction
Insulin resistance (IR) is defined as decreased secretion of insulin from pancreatic β-cells or an insufficient response of peripheral tissues, including adipose tissue and skeletal muscle, to insulin secretion. 1 Insulin resistance, as well as β-cell dysfunction, not only contribute to the progression of type 2 diabetes, 2 but are also important precursors of some chronic diseases, including hypertension, metabolic syndrome, dyslipidemia, and cardiovascular disease (CVD). [3] [4] [5] Insulin resistance has recently received considerable attention, and data reveal that nutritional factors, including food patterns, macronutrients, dietary fiber, and some micronutrients, may be associated with the development of IR. [6] [7] [8] Branched-chain amino acids (BCAAs), including leucine, isoleucine, and valine, are essential amino acids 9 frequently found in dietary protein, accounting for up to 15%-20% of protein intake, that have direct and indirect metabolic effects (e.g. regulation of body weight, muscle protein synthesis, energy homeostasis, food intake control, and glucose homeostasis). [10] [11] [12] Studies on circulating serum concentrations of BCAAs and insulin metabolism or IR have shown controversial findings; some studies indicate impaired BCAA metabolism and increased plasma levels to be associated with a higher risk of IR or type 2 diabetes and preceding hyperglycemia, 9, 13, 14 whereas other studies indicate that increased plasma BCAA concentrations have no effect on insulin sensitivity. 15, 16 Similarly, the limited studies available assessing the association between BCAA intake from the diet and the risk of diabetes have yielded inconsistent results, with one study indicating that a higher intake of these amino acids was associated with a decreased risk of diabetes 17 and the other study reporting that high consumption of BCAAs increases the risk of diabetes. 18 Nevertheless, to date, no population-based cohort study has investigated the association of dietary BCAA intake with the risk of IR and β-cell dysfunction. Thus, the aim of the present study was to assess the association between dietary intake of BCAAs and markers of insulin metabolism among Iranian adults.
Methods

Study population
The present study was conducted within the framework of the Tehran Lipid and Glucose Study (TLGS), an ongoing community-based prospective study aimed at preventing non-communicable diseases (NCD) by developing programs promoting healthy lifestyles and reducing NCD risk factors. 19 The TLGS was conducted on a sample of residents from District No. 13 of Tehran, the capital city of Iran. The baseline survey was a cross-sectional study conducted from 1999 to 2001, and Surveys II (2002-05), III (2006-08), and IV (2009-11) were prospective follow-up surveys.
In the third survey of the TLGS (2006-08), of 12 523 participants, 3462 were randomly selected for dietary assessment. For the present study, 1348 men and women aged ≥20 years, with complete information on insulin, were selected. Subjects with a history of myocardial infarction or stroke (n = 28), those who reported daily energy intakes outside the range of 800-4200 kcal/ day (n = 63), those on specific diets (n = 52), and pregnant and lactating women (n = 25) were excluded; some individuals fell into more than one exclusion category. Finally, 1205 participants were followed until Survey IV , with a median follow-up period of 2.3 years (interquartile range [IQR] 2.0-3.0 years).
The Ethics Committee of the Research Institute for Endocrine Sciences of Shahid Beheshti University of Medical Sciences approved the study protocol, and written informed consent was obtained from all participants.
Measurements
Dietary intake was assessed by expert interviewers, using a food frequency questionnaire (FFQ), 19 the reliability and validity of which have been reported previously. 20 Trained dietitians asked participants in face-to-face interviews to designate their consumption frequency for each food item consumed during the previous year on a daily, weekly, or monthly basis. Portion sizes of consumed foods, reported in household measures, were then converted to grams. Because the Iranian Food Composition Table 21 (FCT) is incomplete, the USDA FCT 22 was used. For national foods not listed in the USDA FCT, the Iranian FCT was the alternative. Amino acid intake was calculated using the USDA FCT (USDA National Nutrient Database for Standard Reference, Release 28, 2015;  http://www.ars.usda.gov/ba/bhnrc/ndl, accessed 15 December 2015), which is based on the chemical analysis of amino acid composition. We assigned values for BCAAs, including leucine, isoleucine, and valine, to each of the FFQ food items. Then, BCAA intake was calculated as the frequency of consumption of each food item multiplied by the leucine, isoleucine, and valine content of the food.
Physical activity was determined using the Modifiable Activity Questionnaire (MAQ) to calculate metabolic equivalent task (MET) minutes per week, which has previously been shown to have high reliability and moderate validity for the Persian translation of the MAQ. 23 Levels of physical activity were categorized as light (MET <600 min/week), moderate (MET 600-1499 min/ week), and vigorous (MET ≥1500 min/week).
Weight, height, waist circumference, systolic blood pressure (SBP), and diastolic blood pressure (DBP) were recorded according to standard protocols, 19 and body mass index (BMI) was calculated as weight (kg) divided by height squared (m 2 ). Blood samples were taken from all participants after an overnight fast of 12-14 h to measure fasting plasma glucose (FPG), 2-h plasma glucose (2-hPG; equivalent to 75 g anhydrous glucose; Cerestar EP, Barcelona, Spain), and fasting serum insulin, as described previously. 19 Hyperinsulinaemia was defined as fasting insulin ≥11.13 and 9.16 μU/mL in women and men, respectively. 24 The homeostatic model assessment of insulin resistance (HOMA-IR) was calculated as follows:
where FINS is fasting insulin (μU/mL) and FPG is fasting plasma glucose (mmol/L). Subjects with HOMA-IR >3.2 were considered to be insulin resistant. β-Cell function was evaluated using the homeostatic model assessment of β-cell function (HOMA-B), calculated as follows:
Values of HOMA-B ≤ 86.2 and 67.1 for women and men, respectively, were considered to indicate β-cell dysfunction. Insulin sensitivity was evaluated using the homeostasis model assessment of insulin sensitivity (HOMA-S), calculated as follows:
Values of HOMA-S ≤ 54.1 and 46.1 for women and men, respectively, were considered to indicate insulin insensitivity.
24,25
Statistical analysis
The present study was a prospective study; information on diet was collected at baseline (2006-08) and serum insulin was measured at baseline and after 3 years of follow-up. Branched-chain amino acids were categorized into tertiles using cut-off points (<2.22%, 2.22-2.64%, and >2.64% of energy). Continuous variables are reported as the mean AE SD or as the median (IQR), whereas categorical variables are reported as percentages. Tests of trend for continuous and categorical variables across BCAA tertiles (using the median value in each tertile) were conducted using linear regression and the Chi-squared test, respectively.
To examine the association of incident hyperinsulinemia, IR, β-cell dysfunction, and insulin insensitivity in each BCAA tertile, multivariable logistic regression models were used and odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. The lowest BCAA tertile (T1) served as the reference group. Model 1 was adjusted for age and sex, and Model 2 was further adjusted for BMI, physical activity, smoking, a family history of diabetes and CVD, hypertension, glycemic load, and daily intakes of energy, saturated fat, and dietary fiber. To calculate the trend of ORs across increasing BCAA categories, we considered the tertile categories as continuous variables. In addition, the ORs of incident hyperinsulinemia, IR, β-cell dysfunction, and insulin insensitivity were estimated across tertiles of leucine, isoleucine, and valine intake using multivariable logistic regression models.
All data were analyzed using SPSS version 15.0 (SPSS Inc., Chicago, IL, USA). Two-sided P < 0.05 was considered significant.
Results
At baseline, the mean (AE SD) age of participants (43% male) was 42.7 AE 13.1 years and the mean BCAA intake was 13.8 AE 5.1 g/day. The incidence of hyperinsulinemia, β-cell dysfunction, insulin insensitivity, and IR was 19.5%, 24.0%, 28.0%, and 12.5%, respectively.
Characteristics of individuals according to BCAA tertile are given in Table 1 . From Table 1 , it can be seen that, across BCAA tertiles, intake of protein and saturated fat increased (P < 0.001), whereas energy, fiber, polyunsaturated fat, and glycemic load decreased (P < 0.001). There was no significant differences in age, sex, BMI, family history of diabetes, family history of CVD, hypertension, physical activity, smoking, FPG, insulin, HOMA-IR, HOMA-B, and HOMA-S across tertiles of BCAA intake (P trend > 0.05 for all). In addition, at the end of the median 2.3-year follow-up period, these characteristics did not differ across tertiles of BCAA intake.
The association between BCAA intake and risk of insulin resistance, hyperinsulinemia, β-cell dysfunction, and insulin insensitivity is given in Table 2 . In the crude model, participants with a higher BCAA intake were 59% more likely to have a risk of insulin resistance (OR 1.59, 95% CI 1.02-2.49), than those with the lowest intake (P trend = 0.032). However, there was no significant association between the dietary intake of BCAAs and the risk of hyperinsulinemia (OR 0.74, 95% CI 0.47-1.17), β-cell dysfunction (OR 0.82, 95% CI 0.55-1.22), or insulin insensitivity (OR 0.8, 95% CI 0.53-1.26). In the final model, after adjusting for all potential confounding variables, subjects in the highest tertile of BCAA intake had a greater risk of developing IR (OR 1.67, 95% CI 1.03-2.71) compared with those in the lowest tertile (P trend = 0.034). However, a higher intake of BCAAs was not significantly associated with hyperinsulinemia (OR 0.74, 95% CI 0.46-1.19), β-cell dysfunction (OR 0.86, 95% CI 0.56-1.31), or insulin insensitivity (OR 0.85, 95% CI 0.54-1.33).
Multivariable-adjusted ORs for insulin resistance, hyperinsulinemia, β-cell dysfunction, and insulin insensitivity across tertiles of leucine, isoleucine, and valine intake are shown in Fig. 1 . Subjects with the highest intake of leucine (OR 1.61, 95% CI 1.01-2.60) and valine (OR 1.75, 95% CI 1.09-2.82) had higher odds of incident IR than those with the lowest intake after adjusting for potential confounding factors (P trend < 0.05). However, a higher intake of isoleucine (OR 1.57, 95% CI 0.96-2.55) was not significantly associated with the risk of incident insulin resistance (Fig. 1a) . In addition, higher intake of leucine, isoleucine, and valine was not significantly related to the incidence of hyperinsulinemia (Fig. 1b) , β-cell dysfunction (Fig. 1c) , or insulin insensitivity (Fig. 1d) . 
Discussion
In the present study we investigated the association between dietary BCAA intake and the risk of IR, β-cell dysfunction, and hyperinsulinemia in 1205 men and women after a 2.3-year follow-up, independent of confounding factors. The findings indicate that a high intake of BCAAs is related to increased risk of IR. However, no significant association was found between dietary BCAA intake and the development of β-cell dysfunction and hyperinsulinemia. In addition, of the BCAAs, a higher intake of leucine and valine was significantly associated with a higher risk of incident IR. Because 80% of serum BCAAs concentrations are determined by the consumption of protein or BCAAs from the diet or supplements and the remaining 20% is related to the catabolism of BCAA metabolites, 26, 27 it can be said that the findings of the present study are comparable with studies showing the association of serum concentrations of circulating BCAAs and IR; 9,13-16 some studies indicated that high BCAA concentrations are related to hyperglycemia, development of IR, and diabetes, 9,13,14 although others found no significant associations between serum concentrations of these amino acids and insulin metabolism. 15, 16 To the best of our knowledge, no previous population-based cohort study has investigated the relationship between dietary BCAA intake and the risk of developing IR; only limited epidemiological studies have investigated the association between BCAA intake and the risk of diabetes, and unfortunately the reported results are inconsistent. 17, 18 In the study of Zheng et al., 18 high dietary BCAA intakes in terms of absolute intake increased the risk of diabetes by nearly 13%. Similarly, in the present study we found a 67% higher risk of IR based on high BCAA intake in terms of the percentage of total energy. However, in another study of a Japanese community, high BCAA intake was associated with a decreased risk of incident diabetes, 17 findings that contrast the findings of the present study. This could be explained by differences in the major food sources contributing to total BCAA intake between the Iranian and Japanese populations. The main sources of BCAAs in the Japanese diet are cereals, potatoes, and starches (23%-25%), fish and shellfish (21%-23%), and meats (14-15%); 17 in Iranian populations, dairy products (38%), cereals (26%), and poultry (12%) are the main sources of dietary BCAAs. As indicated by these two different dietary patterns, there may be nutritional factors contributing to the differences between these two studies. In addition, in the Takayama study population, 17 the range of BCAA intake across tertiles was narrow compared with that in the present study (1-2 difference according to BCAA tertiles vs 4-5 g, respectively), indicating that in the present study there was a considerable difference in BCAA intake between T1 and T3, consequently enabling us to clearly distinguish differences in dietary patterns compared with the Japanese study. 17 Other factors, such as duration of follow-up, confounding factors, and partial differences in the type of outcome assessment (IR vs diabetes), should also be considered when comparing study results. Another interesting point in the present study was that the average BMI of participants was in the overweight range, so some of the increase in IR may be due to obesity. However, the mean BMI did not differ significantly between BCAA tertiles and in both Models 1 and 2 there was a significant increase in the incidence of IR across BCAA tertiles. Furthermore, BMI was adjusted for in the regression models; therefore, some of the increased risk of developing IR can be attributed to dietary BCAAs in the present study.
Recently, several studies assessing the potential therapeutic effects of BCAA supplementation, in particular leucine, on certain metabolic abnormalities (e.g. IR, hyperglycemia, diabetes, and body weight gain) have reported controversial result. [28] [29] [30] [31] Some experimental studies indicated that leucine supplementation improved glucose metabolism and reduced diet-induced IR, especially in high-fat diet-fed mice, by reducing glucose-6-phosphatase gene expression and plasma glucagon levels. 28, 30, 31 However, others reported that high BCAA intake along with a high-protein diet contributes to the development of IR by increasing plasma glucose concentrations and interfering with the intracellular insulin signaling pathway. 29, 32 Therefore, taking these apparently contradictory results into consideration, further studies are needed to explore the role of dietary BCCA intake or supplementation on the risk of IR and the pathogenesis of metabolic abnormalities, such as metabolic syndrome, obesity, and type 2 diabetes.
Although the mechanisms underlying the role of dietary BCAAs on the risk of IR are not yet fully understood, the following mechanisms have been suggested. High serum concentrations of BCAAs persistently activate the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, leading to inhibition of glucose transport in insulin-sensitive tissues, including muscle and fat tissues, and IR with serine phosphorylation of insulin receptor substrate 1 (IRS-1), a condition that occurs in response to persistent hyperinsulinemia or aminoacidemia. 12, 29 This pathway has an important role in critical cellular and developmental processes, such as cell growth, differentiation, cell survival, and metabolism; 33 in fact, activation of mTORC1 signaling by excess dietary BCAAs and activation of ribosomal S6 kinase 1 (S6K1) phosphorylate IRS-1, block insulin intracellular signaling, and increase IR. 12, 14, 34 Of the BCAAs, leucine apparently has greater effects in mediating mTORC1 activity and is more important in the insulin signaling pathway than the other two BCAAs. 12 In addition, other studies have suggested that accumulation of mitotoxic metabolites resulting from the metabolism of BCAAs can increase β-cell mitochondrial dysfunction and stimulate stress kinase signaling and β-cell apoptosis. 12, 35, 36 It is possible that these cell disorders may be associated with IR and the risk of incident diabetes. 12, 35, 36 The present study has some limitations. First, we did not have serum BCAA concentration data for further investigation of the effects of the dietary intake of the different BCAAs on their serum concentrations. Second, although we attempted to adjust for major confounders in the present study, the effects of unknown factors and residual confounding cannot be ruled out. Despite these limitations, the present study has several strengths, including using a valid and reliable FFQ for estimation of dietary BCAAs and other nutrient intake, a long enough follow-up period to detect new cases of IR, and its population-based prospective design.
Conclusion
The present study revealed that high consumption of dietary BCAAs may increase the risk of incident IR and can precede the development of metabolic abnormalities, such as metabolic syndrome and diabetes. However, there was no significant association of dietary BCAA intake with β-cell dysfunction and hyperinsulinemia in adults.
